Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 47,300 shares, a decline of 23.1% from the December 31st total of 61,500 shares. Based on an average trading volume of 122,300 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Entera Bio

A number of institutional investors have recently bought and sold shares of ENTX. Signature Estate & Investment Advisors LLC acquired a new stake in shares of Entera Bio during the 3rd quarter worth $90,000. Parkman Healthcare Partners LLC grew its position in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after acquiring an additional 9,558 shares during the period. Finally, Perigon Wealth Management LLC acquired a new stake in Entera Bio during the fourth quarter worth about $325,000. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Stock Performance

ENTX opened at $2.19 on Friday. Entera Bio has a 12 month low of $0.68 and a 12 month high of $3.35. The business has a 50-day moving average of $2.18 and a two-hundred day moving average of $1.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.